Jiangsu Skyray Instrument Co Ltd
Jiangsu Skyray Instrument Co Ltd designs, develops, and sells medical imaging equipment and related products, primarily in the People's Republic of China.
Business. Jiangsu Skyray Instrument Co Ltd (300165.SZ) is a Chinese manufacturer of industrial machinery and equipment, operating within the Industrial Goods sector. The company is headquartered in China and is primarily listed on the Shenzhen Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Jiangsu Skyray Instrument Co Ltd (300165.SZ) is a Chinese manufacturer of industrial machinery and equipment, operating within the Industrial Goods sector. The company is headquartered in China and is primarily listed on the Shenzhen Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
Jiangsu Skyray Instrument Co Ltd exhibits a debt-to-equity ratio of 1.15, indicating a moderate reliance on debt financing. The company's current ratio of 3.16 suggests it has sufficient short-term assets to cover its liabilities, though its free cash flow of -275.17 million CNY indicates a cash outflow from operations after capital expenditures. The negative net cash position, after subtracting total debt, raises liquidity concerns despite the strong current ratio.
Profitability metrics are weak, with a return on equity of -22.33% and a return on assets of -7.74%. These figures fall significantly below the industry median for medical equipment manufacturers, which typically report positive ROE and ROA in the 5-10% range. The company's operating income of -229.55 million CNY and net loss of -232.83 million CNY for the period highlight a deteriorating financial performance.
The company's revenue is concentrated in a single geographic market, with all disclosed revenue generated in China. No material revenue is attributed to international operations, and no segment disclosures are available in the provided data. This geographic concentration increases exposure to domestic regulatory and economic risks.
Growth trajectory is negative, with a net loss and declining operating income reported in the latest period. No forward-looking revenue guidance is provided, and historical revenue trends are not available in the input data. The absence of positive growth signals and the presence of a net loss suggest a challenging near-term outlook.
Risk factors include a medium liquidity risk due to the negative free cash flow and a net cash position that is negative after subtracting total debt. The dilution risk is assessed as low, with no recent share issuance or ATM/shelf registration activity reported. No dilution sources are identified in the 10-K Risk Factors or recent filings.
Recent events include the filing of a 2023 annual report, which disclosed the net loss and operating income decline. No material earnings call transcripts or regulatory filings are available in the input data to provide further insight into the company's strategic direction or operational challenges.
- Jiangsu Skyray Instrument Co Ltd is experiencing a net loss and declining operating income, with a return on equity of -22.33%.
- The company's debt-to-equity ratio of 1.15 and negative free cash flow of -275.17 million CNY raise liquidity concerns.
- Revenue is entirely concentrated in China, increasing exposure to domestic regulatory and economic risks.
- No material dilution sources are identified, and the dilution risk is assessed as low.
- The company's current ratio of 3.16 provides a buffer against short-term liquidity pressures.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Jiangsu Skyray Instrument Co Ltd Market data — financials · 2026-05-26